Status:
COMPLETED
A Relative Bioavailability Study of LY3454738 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to look at the amount of the study drug, LY3454738 that gets into the blood stream and how long it takes the body to get rid of it when given under the skin comparing...
Eligibility Criteria
Inclusion
- Participants who are overtly healthy as determined by medical history and physical examination.
- Have body mass index (BMI) between 18.0 and 28.0 kilograms per meter squared (kg/m²), inclusive, at screening.
Exclusion
- Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational medicinal product; or of interfering with the interpretation of data.
- Had any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening or intend to during the study.
- Show evidence of active or latent TB.
- Have one of the following infections: hepatitis B virus or human immunodeficiency virus (HIV).
- Participants must not be currently participating in or completed a clinical trial within the last 30 days
Key Trial Info
Start Date :
January 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 2 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06173895
Start Date
January 12 2024
End Date
May 2 2024
Last Update
May 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICON Early Phase Services
San Antonio, Texas, United States, 78209